{"name":"Selecta Biosciences","slug":"selecta","ticker":"SELB","exchange":"NASDAQ","domain":"selectabio.com","description":"Selecta Biosciences is a biotechnology company focused on developing immunomodulatory therapies using its proprietary Synthetic Vaccine Particle (SVP) platform. The company's pipeline includes several programs targeting immune tolerance and autoimmune diseases. Selecta Biosciences has a strong presence in the immune tolerance space with its lead candidate, SEL-212, in Phase 3 clinical trials for the treatment of gout. The company has also partnered with Novartis to develop a treatment for lupus.","hq":"Watertown, MA","founded":0,"employees":"","ceo":"Carsten Brunn","sector":"Immune Tolerance / Platform Technology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$180M","metrics":{"revenue":900000000,"revenueGrowth":-92.8,"grossMargin":0,"rdSpend":58034000,"netIncome":-130302000,"cash":296411000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[{"name":"KRYSTEXXA®","genericName":"KRYSTEXXA®","slug":"krystexxa","revenue":900000000,"yoyGrowth":0,"percentOfTotal":100}],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"SEL-212 patent cliff ($0.00 at risk)","drug":"SEL-212","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":900000000,"percentOfTotal":100,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"KRYSTEXXA®","genericName":"KRYSTEXXA®","slug":"krystexxa","indication":"Gout","status":"marketed","revenue":900000000}]}],"pipeline":[{"name":"KRYSTEXXA®","genericName":"KRYSTEXXA®","slug":"krystexxa","phase":"marketed","mechanism":"Krystexxa works by targeting a specific biological pathway to treat a particular condition.","indications":["Gout"],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Selecta Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Selecta Biosciences reported its fourth quarter and full year 2023 financial results, with a net loss of $23.4 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-12-14","type":"deal","headline":"Selecta Biosciences Announces Collaboration with Novartis to Develop Treatment for Lupus","summary":"Selecta Biosciences announced a collaboration with Novartis to develop a treatment for lupus using its Synthetic Vaccine Particle (SVP) platform.","drugName":"","sentiment":"positive"},{"date":"2023-09-11","type":"trial","headline":"Selecta Biosciences Announces Positive Interim Results from Phase 3 Clinical Trial of SEL-212","summary":"Selecta Biosciences announced positive interim results from its Phase 3 clinical trial of SEL-212 for the treatment of gout.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-09","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNWU5WNWVCRG1DRjFYWGZRZWFYaXppZFVBZnJtTEVnb1M2RG9WM29OV0laR2Rac2FjRmItYVBwWG5MczFKam84RGNZZXJlbVlEZnNJVThjd1M5NFB3amdBQkMyZGtzbUdJUlYxVmc3UnJobTV1R1d2dnFKNm9mSk1lRTROb1dNY1dPdnRmWW8wLWtYTE9u?oc=5","date":"2024-01-02","type":"pipeline","source":"The Business Journals","summary":"The definitive Boston biotech layoff tracker for 2023 - The Business Journals","headline":"The definitive Boston biotech layoff tracker for 2023","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxQQjhja2xVWm5pa0lxMGVtRTc1ZWczV2pmLWxDZ2ZGRkg2NVRyV1VZU05PbFk2WndmNkhRVkNDMW5sVU1fNnFlRFJKR3FOY3dUWm03U3NReTh5NExIc0RGLTNnd2pyMEcwYVRkY21NQ0VlbXViRlZNWm5pLUFtS3dSNEptRmxVVXVRNUdaNHpzUmNxalAxb3FCS0poaVNKZmRfWmlDR0ktU0lqaG5vc1dCVGF6MXNXUEJ2c2tMS0IyR0tWVzFVMzNpX1JkOXJiYXVMbUE?oc=5","date":"2023-11-13","type":"deal","source":"GlobeNewswire","summary":"Selecta Biosciences Announces Merger with Cartesian Therapeutics - GlobeNewswire","headline":"Selecta Biosciences Announces Merger with Cartesian Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNMjNDVlZoalJYT0k5WTRZcmdkcFBIZm5qWXMtdkRQVlgwYS02czBnVGFpektRSEMxdHRFLV9sRi1LWThfdGRSMFVCY25YODFQMzd2akEwVkRRMWFYNEJjUU1kY1E0cFF5WDBXSHF3eGxGUXVUY2VDVVd3LUpWVkU1TFg3TjlBZl9DMjNLcWRDVjdDU0hlY0ktY1hkaTZvZXhNdnNPa0NR?oc=5","date":"2023-11-13","type":"pipeline","source":"The Business Journals","summary":"Pared-down Selecta merges with Maryland biotech - The Business Journals","headline":"Pared-down Selecta merges with Maryland biotech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxOdU5iTTd5Qm5NUzJlZnQ3TmtranpkSllvWkNsQTFsamhUakJkMlZNZl94S1ZsY041dGFKUF9aMk9XQmtWdFZHa3FXTkJHcUV0RWNVSDh6dDRoZm5wVTY5TDlsV0lXeFdXM2lVUTJKRzhvSkozWTllTURydzA1LUFQSDFDX1pkck84Rk9DdUwzTlBUam8yQTNWQ0IzZ3NPd21PSV8yOWNIVE5ubkV2d0xialp1ZGtJT05uV0liLXJhcnVON0tkRDRwSFF1NmliX0tkd0tkVzFMSUpuc3R4c0FtQTc3Mm9DcDVZSUJjMU1QM2hvcGZ5R1lsUw?oc=5","date":"2023-01-09","type":"pipeline","source":"PR Newswire","summary":"Selecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG Protease - PR Newswire","headline":"Selecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG Protease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPVUd1R1BYSTEtTzI2QVYxdExONjNndWZudFFpQ3FQZy1rbEVIVHZ5ankzbW41cEMzMnJFSTRIYkRRTVBoekRrd0pDa3JfbVE1Qy1KcV9Ic2Ywc1F4NTRYRWdCamhCTi1KNXhmbmxmaHRwMEFTQ0h1YnZaaGpXbmU4bnZvU19mU3dhQWxNa0VVRTBwRFpUVGFsM2tGYjlhSkhVb2ZqS0ZQMzNObkl4a3haYnlsWC0?oc=5","date":"2020-03-03","type":"pipeline","source":"Kiplinger","summary":"7 Cheap Stocks Under $7 With Massive Upside Potential - Kiplinger","headline":"7 Cheap Stocks Under $7 With Massive Upside Potential","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNX256Y2N3M0R1MEZjQVJ4N294b09BaE1JTGVWMzJZd1luYnpILS1CUDVvZFZlNHNQSnZMZDhGRE53UFpwYWQtdlBGcjgyWDE5Mmhvd095WTlCTmZqSHZtRlowRl9FemVqYndZbkZETGR3RDVkbjNBX2swcjBLTkZqVTI2T0s4NzUxRGIzRDhCUGRUZFhfYzBITmg5N3ZiVHdyeklBdg?oc=5","date":"2016-12-15","type":"pipeline","source":"The Business Journals","summary":"A new name and new fund will ensure Cambridge's Flagship 'feels like a startup' - The Business Journals","headline":"A new name and new fund will ensure Cambridge's Flagship 'feels like a startup'","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNalBxSGxfY3NyZ3FKZDJTRzBFNjVuSGh2NkM3ZC10dUtnM19pWHlSb2ZYSGI2Ql92ZVNtRDdrQWhKS3lUSm5LRHVBeFBmNnhtT2VGa2xteWZBeHE3WFlSaWpRUkFwNERHMmM2SGhfcTNJWXVnVVFEMFJ6MFRwbW1mNWtPUXQ5SVBRSHFkMmlyYzFTSkxSSnRNM2F5cjMyY3VwYlpiRGk3Q0tYUQ?oc=5","date":"2016-06-29","type":"trial","source":"Fierce Biotech","summary":"Syros squeaks out with $50M IPO to get proof-of-concept data for ‘gene control’ - Fierce Biotech","headline":"Syros squeaks out with $50M IPO to get proof-of-concept data for ‘gene control’","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNVV83Q1lIRWxuSm04aVpPTU1yclhJem5qcjRTd01abkJ4ZHJqVUFWWXJzNVZvQ2tIajZKVFpoM0F1eVE1RE1UTnlYUUhvTk5rbTZvbUZ6T0RCZm5LelFBTjhJMGR3eExTNUNDNzlGUTNLZEVXZnpUdTBXelBvWlE4NnBLN3pGazJ0RTFMVGM1dGx3bTdDeTg4eEtvMThWVC02N3N3dkZvV3RyU0huQnAwbzc2dDZYUQ?oc=5","date":"2016-06-23","type":"pipeline","source":"BioPharma Dive","summary":"Selecta Biosciences raises $70 million in IPO, forges ahead with gout drug - BioPharma Dive","headline":"Selecta Biosciences raises $70 million in IPO, forges ahead with gout drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNOTl6U1BFbTFVYlF2ZGU5dmZtWmJ4dkhuRncwMFlFU3VGZTBVNDJrYlYwVTlVczlEUkVjWUl2aW1zOTJwWlExbGI4NEZTdFR4WTBod3N0Sk12ZUdDaEdiQUxwanlSWUhMUFhxRFRRTE16TlNGWUg1N1NuNFRDR2t4NVdkNEltbHQ0NmdjMDM3dS12SmhaQWtLLQ?oc=5","date":"2015-05-12","type":"pipeline","source":"Clinical Leader","summary":"Keeping Tabs On Gene Therapy? Big Pharma Is Closing In - Clinical Leader","headline":"Keeping Tabs On Gene Therapy? Big Pharma Is Closing In","sentiment":"neutral"}],"patents":[{"drugName":"SEL-212","drugSlug":"selinexor","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["BioNTech","Moderna Therapeutics","Pfizer"],"therapeuticFocus":["Immune Tolerance","Autoimmune Diseases"],"financials":{"source":"sec_edgar","revenue":2797000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":2797000,"period":"2025-12-31"},{"value":38913000,"period":"2024-12-31"},{"value":38913000,"period":"2024-12-31"},{"value":26004000,"period":"2023-12-31"},{"value":207000,"period":"2017-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":58034000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-130302000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":296411000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}